
|Videos|April 26, 2021
A 79-Year-Old Woman With Multiple Myeloma
Author(s)Clifton C. Mo, MD
Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.
Advertisement
Case: A 79-Year-Old Woman with Multiple Myeloma
Initial Presentation
- A 79-year-old woman presented with intermittent nausea, decreased appetite and tingling and numbness in her feet bilaterally
- PMH: HTN, medically controlled
- PE: thin, tired appearing woman, otherwise unremarkable; grade I peripheral neuropathy
- ECOG PS 0
Clinical Workup
- Labs: Hb 9.6 g/dL, calcium 10.5 mg/dL, LDH 210 U/L, creatinine 1.1 mg/dL, albumin 3.8 g/dL, beta-2 microglobulin 3.2 mcg/mL, M-protein 2.9 g/dL, serum free kappa light chains 4.4 mg/dL, CLCr 35mL/min
- Hepatitis B and C negative
- Skeletal survey and MRI showed a lytic lesion in her spine L3/L4
- Bone marrow shows 45% clonal plasma cells IgG k
- FISH: hyperdiploid
- Diagnosis: R-ISS stage I MM
Treatment
- Initiated lenalidomide + bortezomib + dexamethasone for 8 cycles + lenalidomide maintenance for 9 months
- Follow-up at that time revealed disease progression
- Initiated selinexor + bortezomib + dexamethasone
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
Community Clinical Trials and the Lung Cancer Pipeline
4
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
5



























